Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 microg) Interferon Beta-1b (Betaferon / Betaseron) Given Subcutaneously Every Other Day for at Least 36 Months.

Trial Profile

Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 microg) Interferon Beta-1b (Betaferon / Betaseron) Given Subcutaneously Every Other Day for at Least 36 Months.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BENEFIT
  • Sponsors Bayer
  • Most Recent Events

    • 09 Oct 2015 Results will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), as per Bayer media release.
    • 03 May 2014 Patient-reported QOL results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 20 Oct 2011 Results from the 8 year extension study reported in a Bayer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top